JOSEPH PATRICK MCEVOY

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint The costs of schizophrenia
    Joseph P McEvoy
    Department of Clinical Research, Duke University, Butner, NC 27509, USA
    J Clin Psychiatry 68:4-7. 2007
  2. ncbi request reprint Risks versus benefits of different types of long-acting injectable antipsychotics
    Joseph P McEvoy
    John Umstead Hospital, 1003 12th Street, Butner, NC 27509, USA
    J Clin Psychiatry 67:15-8. 2006
  3. ncbi request reprint Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study
    T Scott Stroup
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
    Am J Psychiatry 164:415-27. 2007
  4. ncbi request reprint Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison
    Joseph P McEvoy
    Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:1050-60. 2007
  5. ncbi request reprint A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia
    Joseph P McEvoy
    Duke University Medical Center, John Umstead Hospital AAU, Butner, NC 27509, USA
    J Psychiatr Res 41:895-905. 2007
  6. ncbi request reprint The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder and Tourette's syndrome
    Joseph P McEvoy
    Duke University Medical Center, Durham, NC, USA
    Curr Drug Targets CNS Neurol Disord 1:433-42. 2002
  7. ncbi request reprint Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
    Joseph P McEvoy
    Clinical Research Service, John Umstead Hospital, 1003 12th St, Bldg 32, Butner, NC 27705, USA
    Am J Psychiatry 163:600-10. 2006
  8. ncbi request reprint Functional outcomes in schizophrenia
    Joseph P McEvoy
    Duke University Medical Center, Durham, NC, USA
    J Clin Psychiatry 69:20-4. 2008
  9. ncbi request reprint Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III
    Joseph P McEvoy
    Department of Psychiatry and Behavioral Sciences, Duke University, Clinical Research, John Umstead Hospital, 1003 12th Street, Butner, NC 27509, USA
    Schizophr Res 80:19-32. 2005
  10. ncbi request reprint Insight in first-episode psychosis
    Joseph P McEvoy
    John Umstead Hospital, Duke University Department of Psychiatry, Butner, NC 27509, USA
    Psychol Med 36:1385-93. 2006

Detail Information

Publications65

  1. ncbi request reprint The costs of schizophrenia
    Joseph P McEvoy
    Department of Clinical Research, Duke University, Butner, NC 27509, USA
    J Clin Psychiatry 68:4-7. 2007
    ..When interpreting any data regarding costs, people should be aware of factors that influence results, such as the perspective from which the analysis was undertaken, the measures used in the analysis, and planned or unplanned bias...
  2. ncbi request reprint Risks versus benefits of different types of long-acting injectable antipsychotics
    Joseph P McEvoy
    John Umstead Hospital, 1003 12th Street, Butner, NC 27509, USA
    J Clin Psychiatry 67:15-8. 2006
    ..By preventing or delaying relapse, consistent treatment can improve the patient's quality of life and lead to an overall reduction in the cost of care...
  3. ncbi request reprint Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study
    T Scott Stroup
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
    Am J Psychiatry 164:415-27. 2007
    ..This randomized, double-blind study compared olanzapine, quetiapine, and risperidone in patients who had just discontinued the older antipsychotic perphenazine...
  4. ncbi request reprint Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison
    Joseph P McEvoy
    Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:1050-60. 2007
    ....
  5. ncbi request reprint A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia
    Joseph P McEvoy
    Duke University Medical Center, John Umstead Hospital AAU, Butner, NC 27509, USA
    J Psychiatr Res 41:895-905. 2007
    ..Aripiprazole 10 mg/day is effective and well tolerated for patients experiencing an acute exacerbation of schizophrenia...
  6. ncbi request reprint The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder and Tourette's syndrome
    Joseph P McEvoy
    Duke University Medical Center, Durham, NC, USA
    Curr Drug Targets CNS Neurol Disord 1:433-42. 2002
    ..Nicotine delivered by gum or transdermal patch can provide short term relief for exacerbations of Tourette's Syndrome, but its use is limited by frequent toxicity, primarily nausea...
  7. ncbi request reprint Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
    Joseph P McEvoy
    Clinical Research Service, John Umstead Hospital, 1003 12th St, Bldg 32, Butner, NC 27705, USA
    Am J Psychiatry 163:600-10. 2006
    ....
  8. ncbi request reprint Functional outcomes in schizophrenia
    Joseph P McEvoy
    Duke University Medical Center, Durham, NC, USA
    J Clin Psychiatry 69:20-4. 2008
    ..The panel deferred the task of establishing operational criteria for recovery since there was insufficient research on the topic. This article provides a summary of this still "uncharted" aspect of treatment...
  9. ncbi request reprint Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III
    Joseph P McEvoy
    Department of Psychiatry and Behavioral Sciences, Duke University, Clinical Research, John Umstead Hospital, 1003 12th Street, Butner, NC 27509, USA
    Schizophr Res 80:19-32. 2005
    ..One important risk factor for cardiovascular disease is the metabolic syndrome (MS), yet limited data exist on its prevalence in US patients with schizophrenia...
  10. ncbi request reprint Insight in first-episode psychosis
    Joseph P McEvoy
    John Umstead Hospital, Duke University Department of Psychiatry, Butner, NC 27509, USA
    Psychol Med 36:1385-93. 2006
    ....
  11. ncbi request reprint Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    J Nerv Ment Dis 194:164-72. 2006
    ....
  12. ncbi request reprint Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Psychiatr Serv 57:1110-6. 2006
    ..This study examined the relationship between substance use and psychosocial functioning in schizophrenia...
  13. ncbi request reprint Aripiprazole: pharmacology, efficacy, safety and tolerability
    Warren A Kinghorn
    Duke University Medical Center, Department of Psychiatry and Behavioral Sciences, Durham, NC 27710, USA
    Expert Rev Neurother 5:297-307. 2005
    ..Further studies and postmarketing data will be helpful in providing additional information about the comparative safety, efficacy and tolerability of aripiprazole...
  14. ncbi request reprint Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:428-36. 2007
    ..This study examined the relative effects of the second-generation antipsychotic drugs and an older representative agent on psychosocial functioning in patients with chronic schizophrenia...
  15. ncbi request reprint Baseline neurocognitive deficits in the CATIE schizophrenia trial
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Neuropsychopharmacology 31:2033-46. 2006
    ..Multiple analyses suggested that a broad cognitive deficit characterizes this sample. These deficits are modestly related to negative symptoms and essentially independent of positive symptom severity...
  16. ncbi request reprint Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
    ..The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined...
  17. ncbi request reprint A national study of violent behavior in persons with schizophrenia
    Jeffrey W Swanson
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 63:490-9. 2006
    ..Violent behavior is uncommon, yet problematic, among schizophrenia patients. The complex effects of clinical, interpersonal, and social-environmental risk factors for violence in this population are poorly understood...
  18. ncbi request reprint Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Am J Psychiatry 164:1061-71. 2007
    ..The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis...
  19. pmc Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis
    Anna C Need
    Center for Human Genome Variation, Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Eur J Hum Genet 17:946-57. 2009
    ..On current evidence it is impossible to know which of these associations may be real, although in total they form a valuable resource that is immediately available to the scientific community...
  20. ncbi request reprint Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources
    Richard S E Keefe
    Department of Psychiatry and Behavioural Science, Duke University Medical Center, P O Box 3270, Durham, NC 27710, USA
    Schizophr Res 57:51-67. 2002
    ..This deficit, termed autonoetic agnosia, may result in the conclusion that self-generated thoughts come from an external source...
  21. pmc Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
    Jeffrey W Swanson
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, 905 West Main Street, Durham, NC 27710, USA
    Br J Psychiatry 193:37-43. 2008
    ..Violence is an uncommon but significant problem associated with schizophrenia...
  22. doi request reprint What CATIE found: results from the schizophrenia trial
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Psychiatr Serv 59:500-6. 2008
    ..Patient characteristics and clinical circumstances affected drug effectiveness; these patient factors are important in making treatment choices...
  23. ncbi request reprint Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications
    Richard S E Keefe
    Duke University Medical Center, Box 3270, Durham, NC 27710, USA
    Psychopharmacology (Berl) 169:383-9. 2003
    ....
  24. doi request reprint The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham NC 27710, United States
    Schizophr Res 100:39-52. 2008
    ..This double-blind study compared a second generation (atypical) antipsychotic drugs compared to a representative older agent for patients with schizophrenia who use or avoid illicit substances...
  25. ncbi request reprint Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3173, Durham, NC 27710, USA
    Schizophr Bull 29:33-43. 2003
    ....
  26. ncbi request reprint Project among African-Americans to explore risks for schizophrenia (PAARTNERS): recruitment and assessment methods
    Muktar H Aliyu
    Department of Psychiatry, University of Alabama at Birmingham, Birmingham, AL 35294 2041, and Duke University Medical Center John Umstead Hospital, Butner, NC, United States
    Schizophr Res 87:32-44. 2006
    ..This novel integration of diagnostic, neurocognitive and genetic data will also generate valuable information for future phenotypic and genetic studies of schizophrenia...
  27. ncbi request reprint An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
    Joseph P McEvoy
    Department of Psychiatry, Duke University Medical Center, Durham, NC 27509, USA
    CNS Spectr 11:4-8. 2006
  28. ncbi request reprint Smoking and psychosis in patients with bipolar I disorder
    Frederick Cassidy
    Department of Psychiatry, Duke University Medical Center, Durham, NC, USA
    Compr Psychiatry 43:63-4. 2002
    ..Smoking did not associate with psychosis in any of our analyses...
  29. pmc Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study
    Iris Grossman
    Institute for Genome Sciences and Policy, Center for Population Genomics and Pharmacogenetics, Duke University, Durham, North Carolina, USA
    Genet Med 10:720-9. 2008
    ..To evaluate systematically in real clinical settings whether functional genetic variations in drug metabolizing enzymes influence optimized doses, efficacy, and safety of antipsychotic medications...
  30. ncbi request reprint Sensory acuity and reasoning in delusional disorder
    Charles R Conway
    Duke University Department of Psychiatry, John Umstead Hospital, Butner, NC 27509, USA
    Compr Psychiatry 43:175-8. 2002
    ..Further, the study suggests that this reasoning difference generalizes to events outside the DD subjects' delusional realm and can be evoked in an experimental environment...
  31. pmc A genome-wide investigation of SNPs and CNVs in schizophrenia
    Anna C Need
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    PLoS Genet 5:e1000373. 2009
    ..On balance, these data suggest that very few schizophrenia patients share identical genomic causation, potentially complicating efforts to personalize treatment regimens...
  32. ncbi request reprint The importance of early treatment of schizophrenia
    Joseph P McEvoy
    Duke University Medical Center, North Carolina, USA
    Behav Healthc 27:40-3. 2007
    ..Providers should treat their patients with respect, express their viewpoint succinctly and consistently, and make clear that the betterment of the patient is their goal...
  33. ncbi request reprint Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
    Diana O Perkins
    Department of Psychiatry, C B 7160, University of North Carolina School of Medicine, Chapel Hill, 27599 7160, USA
    Schizophr Res 83:53-63. 2006
    ..Factors associated with treatment adherence in patients with chronic schizophrenia include beliefs about severity of illness and need for treatment, treatment with typical versus atypical antipsychotic and medication side effects...
  34. ncbi request reprint Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol
    Jan Volavka
    Nathan Kline Institute, Orangeburg, NY 10982, USA
    J Clin Psychiatry 65:57-61. 2004
    ....
  35. ncbi request reprint The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update
    Troy A Moore
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, USA
    J Clin Psychiatry 68:1751-62. 2007
    ....
  36. ncbi request reprint The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development
    T Scott Stroup
    Department of Psychiatry, University of North Carolina School of Medicine, Neurosciences Hospital, Chapel Hill 27599 7160, USA
    Schizophr Bull 29:15-31. 2003
    ..If the phase 2 study drug is discontinued, subjects may enter phase 3, in which clinicians help subjects select an open-label treatment based on individuals' experiences in phases 1 and 2...
  37. pmc Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, USA
    Schizophr Res 101:273-86. 2008
    ..Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial...
  38. pmc Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia
    S Kristian Hill
    Center for Cognitive Medicine, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    J Int Neuropsychol Soc 14:209-21. 2008
    ....
  39. ncbi request reprint Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics
    Jean Pierre Lindenmayer
    Nathan Kline Institute fo Psychiatric Research, New York, NY 10035, USA
    Am J Psychiatry 160:290-6. 2003
    ....
  40. ncbi request reprint Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia
    Yen Kuang Yang
    National Cheng Kung University, 138 Sheng Li Road, Tainan 704, Taiwan
    Schizophr Res 60:9-12. 2003
    ..All measures demonstrated good test-retest reliability. Objective measures of smoking were consistently intercorrelated and should be the preferred outcome measures in studies testing strategies to reduce smoking...
  41. ncbi request reprint Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study
    Jean Pierre Lindenmayer
    Psychopharmacology Research Unit, Manhattan Psychiatric Center, Wards Island, NY 10035, USA
    J Clin Psychiatry 63:931-5. 2002
    ....
  42. ncbi request reprint Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia
    Yen Kuang Yang
    National Cheng Kung University, Taiwan, China
    Neuropsychopharmacology 27:684-6. 2002
    ..Clinical assessments of bradykinesia-rigidity were lower during nicotine patch administration than during placebo patch administration...
  43. pmc Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, VA San Diego Healthcare System, San Diego, CA 92161, United States
    Schizophr Res 103:104-9. 2008
    ..Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial...
  44. doi request reprint Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
    Bruce J Kinon
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:392-400. 2008
    ....
  45. ncbi request reprint Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Biol Psychiatry 52:701-7. 2002
    ....
  46. ncbi request reprint Galantamine for treatment-resistant schizophrenia
    Trina B Allen
    Am J Psychiatry 159:1244-5. 2002
  47. ncbi request reprint Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    Am J Psychiatry 159:255-62. 2002
    ....
  48. ncbi request reprint The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update
    Alexander L Miller
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, MC 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    J Clin Psychiatry 65:500-8. 2004
    ..This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators...
  49. ncbi request reprint Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia
    Jean Pierre Lindenmayer
    Nathan Kline Institute, Orangeburg, N Y, USA
    J Clin Psychiatry 65:551-6. 2004
    ..We are exploring whether this expanded clinical efficacy can also be seen in patients with treatment-resistant schizophrenia...
  50. ncbi request reprint Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study
    Diana O Perkins
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, USA
    J Clin Psychiatry 69:106-13. 2008
    ..To evaluate predictors of treatment discontinuation against medical advice and poor medication adherence among first-episode patients treated with olanzapine, quetiapine, or risperidone...
  51. ncbi request reprint Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
    Robert B Zipursky
    Schizophrenia Programme, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Br J Psychiatry 187:537-43. 2005
    ..Substantial weight gain is common with many atypical antipsychotics...
  52. ncbi request reprint Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 163:611-22. 2006
    ..This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic...
  53. ncbi request reprint A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
    Donald C Goff
    Massachusetts General Hospital, Harvard Medical School, Department of Psychiatry 25 Staniford Street, Boston, MA 02114, USA
    Schizophr Res 80:45-53. 2005
    ..The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, despite recent concerns about metabolic complications of certain atypical antipsychotics...
  54. ncbi request reprint Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
    ..We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study...
  55. ncbi request reprint Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial
    Del D Miller
    University of Iowa Carver College of Medicine, Psychiatry Research, 2 105 MEB, 500 Newton Rd, Iowa City, IA 52242 1000, USA
    Schizophr Res 80:33-43. 2005
    ..To examine the clinical characteristics of individuals with schizophrenia that develop tardive dyskinesia (TD) associated with antipsychotic treatment...
  56. ncbi request reprint Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia
    Daniel J Muller
    Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Eur Neuropsychopharmacol 15:525-31. 2005
    ..8 to 7%. Our results further suggest that this effect is only attributable to Caucasians when compared to African-Americans. Moreover, our findings point to the role of intracellular mechanisms in antipsychotic response...
  57. ncbi request reprint The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome
    Jonathan M Meyer
    VA San Diego Healthcare System, USA
    Schizophr Res 80:9-18. 2005
    ....
  58. ncbi request reprint Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia
    Lydia A Chwastiak
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    Psychiatr Serv 57:1102-9. 2006
    ....
  59. ncbi request reprint The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia
    Daniel J Muller
    Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College Street R30, Toronto, Ont M5T 1R8, Canada
    Neurosci Lett 379:81-9. 2005
    ..Weight changes do not seem to be associated with polymorphism of the SNAP-25 gene, however, replication in independent samples is warranted...
  60. ncbi request reprint Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline
    Henry A Nasrallah
    University of Cincinnati, Cincinnati, OH 45267 0559, USA
    Schizophr Res 86:15-22. 2006
    ....
  61. ncbi request reprint Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment
    Vincenzo De Luca
    Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College Street R 30, Toronto, Ont, Canada M5T 1R8
    Pharmacol Res 51:381-4. 2005
    ..Our results suggest that the novel polymorphism may not play a major role in antipsychotic response...
  62. ncbi request reprint Revised PORT recommendations
    T Scott Stroup
    University of North Carolina at Chapel Hill, 10626 Neurosciences Hospital, Campus Box 7160, Chapel Hill, NC 27599 7160, USA
    Schizophr Bull 30:609-11. 2004
  63. ncbi request reprint Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia
    John Lauriello
    Department of Psychiatry MSC095030, 1 University of New Mexico Health Sciences Center, Albuquerque, NM 87131 001, USA
    Schizophr Res 72:249-58. 2005
    ..5%; P < 0.01). Long-acting risperidone was well tolerated. Long-acting risperidone initiated during inpatient treatment may be an important strategy in improving long-term outcomes among patients with schizophrenia...
  64. ncbi request reprint Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    J Clin Psychopharmacol 24:225-8. 2004
    ..Clozapine appears to have superior antiaggresive effects in treatment-resistant patients; this superiority develops after the patient has been exposed to an adequate dose regimen...
  65. ncbi request reprint Determining when impairment constitutes incapacity for informed consent in schizophrenia research
    Scott Y H Kim
    Department of Psychiatry, Bioethics Program, and Center for Behavioral and Decision Sciences in Medicine, University of Michigan, 300 North Ingalls, Ann Arbor, MI 48109 0429, and Massachusetts General Hospital, Boston, USA
    Br J Psychiatry 191:38-43. 2007
    ..Although people with schizophrenia display impaired abilities for consent, it is not known how much impairment constitutes incapacity...

Research Grants7

  1. Schizophenia Libility Genes among African-Americans
    Joseph McEvoy; Fiscal Year: 2006
    ..Finally, we have an outstanding track record of African American participation in research studies, and a deep appreciation of their population genetics. ..
  2. 1/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS
    JOSEPH PATRICK MCEVOY; Fiscal Year: 2010
    ..We will determine if the new preparation keeps patients free of psychotic relapse for a significantly longer time. ..